Axsome Therapeutics (AXSM) Accumulated Expenses (2015 - 2026)

Axsome Therapeutics' Accumulated Expenses history runs 12 years deep, the most recent figure standing at $43000.0 for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 99.96% year-over-year to $43000.0; the TTM figure through Mar 2026 stood at $43000.0 (down 99.96% YoY), while the FY2025 annual figure was $150.2 million, up 941.14% from the prior year.
• Accumulated Expenses came in at $43000.0 for Q1 2026 at Axsome Therapeutics, down from $150.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $150.2 million in Q4 2025 to a low of $43000.0 in Q1 2026.
• A 5-year average of $22.5 million and a median of $4.5 million in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses soared 5672.63% in 2025 and slumped 99.96% in 2026, its largest moves.
• Axsome Therapeutics' Accumulated Expenses stood at $875000.0 in 2022, then jumped by 643.2% to $6.5 million in 2023, then surged by 121.91% to $14.4 million in 2024, then surged by 941.14% to $150.2 million in 2025, then plunged by 99.97% to $43000.0 in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $43000.0, $150.2 million, and $7.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison